Gloria González Aseguinolaza-rekin lankidetzan egindako argitalpenak (10)

2024

  1. Enhanced AAV transduction across preclinical CNS models: A comparative study in human brain organoids with cross-species evaluations

    Molecular Therapy Nucleic Acids, Vol. 35, Núm. 3

  2. GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model

    Translational Neurodegeneration

2023

  1. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

  2. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

    Neurobiology of Disease, Vol. 183

2022

  1. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease

    Molecular Therapy - Methods and Clinical Development, Vol. 26, pp. 98-106

2021

  1. Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

2017

  1. Adeno-associated viral vectors serotype 8 for cell-specific delivery of therapeutic genes in the central nervous system

    Frontiers in Neuroanatomy, Vol. 11

2014

  1. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice

    EMBO Molecular Medicine, Vol. 6, Núm. 10, pp. 1246-1262

2011

  1. Adeno-associated virus liver transduction efficiency measured by in vivo [ 18F]FHBG positron emission tomography imaging in rodents and nonhuman primates

    Human Gene Therapy, Vol. 22, Núm. 8, pp. 999-1009